nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Temozolomide—malignant glioma	0.438	1	CbGbCtD
Maraviroc—Hemianopia—Temozolomide—malignant glioma	0.0301	0.0925	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—IL12A—malignant glioma	0.0117	0.0496	CbGpPWpGaD
Maraviroc—Facial paralysis—Carmustine—malignant glioma	0.0113	0.0347	CcSEcCtD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCR4—malignant glioma	0.0111	0.0468	CbGpPWpGaD
Maraviroc—Meningitis—Carmustine—malignant glioma	0.00926	0.0285	CcSEcCtD
Maraviroc—CCR5—Peptide GPCRs—CCR4—malignant glioma	0.00885	0.0374	CbGpPWpGaD
Maraviroc—VIIth nerve paralysis—Carmustine—malignant glioma	0.00875	0.0269	CcSEcCtD
Maraviroc—Opportunistic infection—Temozolomide—malignant glioma	0.00861	0.0265	CcSEcCtD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCR3—malignant glioma	0.00822	0.0347	CbGpPWpGaD
Maraviroc—Altered state of consciousness—Temozolomide—malignant glioma	0.00752	0.0231	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—IL12B—malignant glioma	0.00738	0.0312	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CXCR3—malignant glioma	0.00658	0.0278	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—BDKRB2—malignant glioma	0.00602	0.0254	CbGpPWpGaD
Maraviroc—Transaminases increased—Carmustine—malignant glioma	0.0059	0.0181	CcSEcCtD
Maraviroc—CCR5—GPCRs, Other—CXCR3—malignant glioma	0.00558	0.0236	CbGpPWpGaD
Maraviroc—Cyst—Carmustine—malignant glioma	0.00537	0.0165	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—HLA-A—malignant glioma	0.00475	0.0201	CbGpPWpGaD
Maraviroc—Scotoma—Carmustine—malignant glioma	0.00473	0.0145	CcSEcCtD
Maraviroc—Hepatotoxicity—Carmustine—malignant glioma	0.00465	0.0143	CcSEcCtD
Maraviroc—Herpes zoster—Temozolomide—malignant glioma	0.00461	0.0142	CcSEcCtD
Maraviroc—Scotoma—Temozolomide—malignant glioma	0.00457	0.014	CcSEcCtD
Maraviroc—Hepatotoxicity—Temozolomide—malignant glioma	0.00449	0.0138	CcSEcCtD
Maraviroc—Coagulopathy—Temozolomide—malignant glioma	0.00446	0.0137	CcSEcCtD
Maraviroc—Otitis media—Temozolomide—malignant glioma	0.00446	0.0137	CcSEcCtD
Maraviroc—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00422	0.013	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCR4—malignant glioma	0.00416	0.0176	CbGpPWpGaD
Maraviroc—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.00382	0.0117	CcSEcCtD
Maraviroc—CYP3A4—Liver X Receptor Pathway—CYP2B6—malignant glioma	0.00377	0.0159	CbGpPWpGaD
Maraviroc—Herpes simplex—Temozolomide—malignant glioma	0.00377	0.0116	CcSEcCtD
Maraviroc—Respiratory failure—Temozolomide—malignant glioma	0.00353	0.0109	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—CCR4—malignant glioma	0.00351	0.0148	CbGpPWpGaD
Maraviroc—Influenza like illness—Temozolomide—malignant glioma	0.00337	0.0104	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCR4—malignant glioma	0.00326	0.0138	CbGpPWpGaD
Maraviroc—Neoplasm—Carmustine—malignant glioma	0.00325	0.00998	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—IFNG—malignant glioma	0.00317	0.0134	CbGpPWpGaD
Maraviroc—Neoplasm—Temozolomide—malignant glioma	0.00314	0.00964	CcSEcCtD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL8—malignant glioma	0.00312	0.0132	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCR3—malignant glioma	0.00309	0.0131	CbGpPWpGaD
Maraviroc—Diabetes mellitus—Carmustine—malignant glioma	0.003	0.00921	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.0029	0.0089	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—PTPN11—malignant glioma	0.00284	0.012	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—BDKRB2—malignant glioma	0.00283	0.012	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL1B—malignant glioma	0.00283	0.012	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—malignant glioma	0.00282	0.0119	CbGpPWpGaD
Maraviroc—Vascular purpura—Temozolomide—malignant glioma	0.00282	0.00866	CcSEcCtD
Maraviroc—Deafness—Temozolomide—malignant glioma	0.00282	0.00866	CcSEcCtD
Maraviroc—Hepatic failure—Temozolomide—malignant glioma	0.0028	0.00862	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCR4—malignant glioma	0.00279	0.0118	CbGpPWpGaD
Maraviroc—Amnesia—Carmustine—malignant glioma	0.00277	0.00853	CcSEcCtD
Maraviroc—Nasal congestion—Temozolomide—malignant glioma	0.00276	0.0085	CcSEcCtD
Maraviroc—Amnesia—Temozolomide—malignant glioma	0.00268	0.00824	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Temozolomide—malignant glioma	0.00267	0.00821	CcSEcCtD
Maraviroc—Purpura—Temozolomide—malignant glioma	0.00261	0.00803	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—CXCR3—malignant glioma	0.00261	0.011	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—KNG1—malignant glioma	0.00257	0.0109	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—POR—malignant glioma	0.00255	0.0108	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CXCR3—malignant glioma	0.00242	0.0102	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—BDKRB2—malignant glioma	0.00239	0.0101	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—STAT3—malignant glioma	0.00237	0.01	CbGpPWpGaD
Maraviroc—Breast disorder—Temozolomide—malignant glioma	0.00228	0.007	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—RAF1—malignant glioma	0.00227	0.0096	CbGpPWpGaD
Maraviroc—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00227	0.00697	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.00227	0.00697	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00222	0.00683	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—BDKRB2—malignant glioma	0.00222	0.00936	CbGpPWpGaD
Maraviroc—Abdominal distension—Temozolomide—malignant glioma	0.00219	0.00674	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—KNG1—malignant glioma	0.00217	0.00918	CbGpPWpGaD
Maraviroc—CYP3A4—Xenobiotics—CYP2B6—malignant glioma	0.00217	0.00916	CbGpPWpGaD
Maraviroc—Pancytopenia—Carmustine—malignant glioma	0.00214	0.00658	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CCR4—malignant glioma	0.00213	0.00899	CbGpPWpGaD
Maraviroc—Neutropenia—Carmustine—malignant glioma	0.00211	0.00648	CcSEcCtD
Maraviroc—Bronchitis—Temozolomide—malignant glioma	0.00209	0.00644	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCR3—malignant glioma	0.00208	0.00877	CbGpPWpGaD
Maraviroc—Pancytopenia—Temozolomide—malignant glioma	0.00207	0.00635	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—IL1B—malignant glioma	0.00205	0.00864	CbGpPWpGaD
Maraviroc—Neutropenia—Temozolomide—malignant glioma	0.00204	0.00626	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00202	0.00622	CcSEcCtD
Maraviroc—Pneumonia—Carmustine—malignant glioma	0.00202	0.00621	CcSEcCtD
Maraviroc—Depression—Carmustine—malignant glioma	0.002	0.00616	CcSEcCtD
Maraviroc—Renal failure—Carmustine—malignant glioma	0.00197	0.00607	CcSEcCtD
Maraviroc—Neuropathy peripheral—Carmustine—malignant glioma	0.00197	0.00605	CcSEcCtD
Maraviroc—Stomatitis—Carmustine—malignant glioma	0.00196	0.00602	CcSEcCtD
Maraviroc—Pneumonia—Temozolomide—malignant glioma	0.00195	0.006	CcSEcCtD
Maraviroc—Infestation NOS—Temozolomide—malignant glioma	0.00194	0.00597	CcSEcCtD
Maraviroc—Infestation—Temozolomide—malignant glioma	0.00194	0.00597	CcSEcCtD
Maraviroc—Depression—Temozolomide—malignant glioma	0.00194	0.00595	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00192	0.00592	CcSEcCtD
Maraviroc—Neuropathy peripheral—Temozolomide—malignant glioma	0.0019	0.00585	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	0.0019	0.00802	CbGpPWpGaD
Maraviroc—Stomatitis—Temozolomide—malignant glioma	0.00189	0.00582	CcSEcCtD
Maraviroc—CYP3A4—Xenobiotics—CYP2C18—malignant glioma	0.00188	0.00794	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Temozolomide—malignant glioma	0.00184	0.00564	CcSEcCtD
Maraviroc—Sinusitis—Temozolomide—malignant glioma	0.00182	0.0056	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—LATS2—malignant glioma	0.00182	0.00768	CbGpPWpGaD
Maraviroc—Hallucination—Carmustine—malignant glioma	0.00179	0.00551	CcSEcCtD
Maraviroc—Connective tissue disorder—Carmustine—malignant glioma	0.00177	0.00545	CcSEcCtD
Maraviroc—CYP3A4—Irinotecan Pathway—BCHE—malignant glioma	0.00176	0.00744	CbGpPWpGaD
Maraviroc—Hallucination—Temozolomide—malignant glioma	0.00173	0.00533	CcSEcCtD
Maraviroc—Pharyngitis—Temozolomide—malignant glioma	0.00173	0.00532	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	0.00173	0.0073	CbGpPWpGaD
Maraviroc—Urinary tract disorder—Temozolomide—malignant glioma	0.00172	0.00529	CcSEcCtD
Maraviroc—Connective tissue disorder—Temozolomide—malignant glioma	0.00171	0.00526	CcSEcCtD
Maraviroc—Urethral disorder—Temozolomide—malignant glioma	0.00171	0.00525	CcSEcCtD
Maraviroc—CCR5—HIV Infection—HLA-A—malignant glioma	0.00171	0.00721	CbGpPWpGaD
Maraviroc—Eye disorder—Carmustine—malignant glioma	0.00169	0.00518	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—F2—malignant glioma	0.00166	0.00703	CbGpPWpGaD
Maraviroc—Erythema multiforme—Temozolomide—malignant glioma	0.00165	0.00506	CcSEcCtD
Maraviroc—Eye disorder—Temozolomide—malignant glioma	0.00163	0.00501	CcSEcCtD
Maraviroc—Cardiac disorder—Temozolomide—malignant glioma	0.00162	0.00497	CcSEcCtD
Maraviroc—Alopecia—Carmustine—malignant glioma	0.00159	0.0049	CcSEcCtD
Maraviroc—Angiopathy—Temozolomide—malignant glioma	0.00158	0.00486	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CXCR3—malignant glioma	0.00158	0.00668	CbGpPWpGaD
Maraviroc—Mental disorder—Carmustine—malignant glioma	0.00158	0.00486	CcSEcCtD
Maraviroc—Mediastinal disorder—Temozolomide—malignant glioma	0.00157	0.00483	CcSEcCtD
Maraviroc—Malnutrition—Carmustine—malignant glioma	0.00157	0.00482	CcSEcCtD
Maraviroc—Erythema—Carmustine—malignant glioma	0.00157	0.00482	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—ASMT—malignant glioma	0.00156	0.0066	CbGpPWpGaD
Maraviroc—Alopecia—Temozolomide—malignant glioma	0.00154	0.00473	CcSEcCtD
Maraviroc—Mental disorder—Temozolomide—malignant glioma	0.00153	0.00469	CcSEcCtD
Maraviroc—Erythema—Temozolomide—malignant glioma	0.00152	0.00466	CcSEcCtD
Maraviroc—Malnutrition—Temozolomide—malignant glioma	0.00152	0.00466	CcSEcCtD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	0.00149	0.00629	CbGpPWpGaD
Maraviroc—Tremor—Carmustine—malignant glioma	0.00147	0.00452	CcSEcCtD
Maraviroc—Anaemia—Carmustine—malignant glioma	0.00145	0.00446	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—BDKRB2—malignant glioma	0.00145	0.00611	CbGpPWpGaD
Maraviroc—Tremor—Temozolomide—malignant glioma	0.00142	0.00437	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2B6—malignant glioma	0.00142	0.00599	CbGpPWpGaD
Maraviroc—Leukopenia—Carmustine—malignant glioma	0.00141	0.00432	CcSEcCtD
Maraviroc—Anaemia—Temozolomide—malignant glioma	0.0014	0.00431	CcSEcCtD
Maraviroc—CCR5—Disease—BCAN—malignant glioma	0.0014	0.00592	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LATS1—malignant glioma	0.00138	0.00582	CbGpPWpGaD
Maraviroc—Convulsion—Carmustine—malignant glioma	0.00136	0.00418	CcSEcCtD
Maraviroc—Leukopenia—Temozolomide—malignant glioma	0.00136	0.00417	CcSEcCtD
Maraviroc—Myalgia—Carmustine—malignant glioma	0.00134	0.00411	CcSEcCtD
Maraviroc—Anxiety—Carmustine—malignant glioma	0.00133	0.00409	CcSEcCtD
Maraviroc—Cough—Temozolomide—malignant glioma	0.00132	0.00407	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—KNG1—malignant glioma	0.00132	0.00556	CbGpPWpGaD
Maraviroc—Convulsion—Temozolomide—malignant glioma	0.00131	0.00404	CcSEcCtD
Maraviroc—Myalgia—Temozolomide—malignant glioma	0.00129	0.00397	CcSEcCtD
Maraviroc—Anxiety—Temozolomide—malignant glioma	0.00129	0.00396	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00128	0.00394	CcSEcCtD
Maraviroc—Oedema—Carmustine—malignant glioma	0.00128	0.00394	CcSEcCtD
Maraviroc—Discomfort—Temozolomide—malignant glioma	0.00128	0.00392	CcSEcCtD
Maraviroc—Infection—Carmustine—malignant glioma	0.00127	0.00391	CcSEcCtD
Maraviroc—CCR5—Disease—DTX1—malignant glioma	0.00127	0.00535	CbGpPWpGaD
Maraviroc—Oedema—Temozolomide—malignant glioma	0.00124	0.00381	CcSEcCtD
Maraviroc—Infection—Temozolomide—malignant glioma	0.00123	0.00378	CcSEcCtD
Maraviroc—Anorexia—Carmustine—malignant glioma	0.00122	0.00375	CcSEcCtD
Maraviroc—Nervous system disorder—Temozolomide—malignant glioma	0.00121	0.00373	CcSEcCtD
Maraviroc—Skin disorder—Temozolomide—malignant glioma	0.0012	0.0037	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CCR4—malignant glioma	0.0012	0.00508	CbGpPWpGaD
Maraviroc—Anorexia—Temozolomide—malignant glioma	0.00118	0.00363	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL8—malignant glioma	0.00117	0.00496	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00117	0.00359	CcSEcCtD
Maraviroc—Insomnia—Carmustine—malignant glioma	0.00116	0.00356	CcSEcCtD
Maraviroc—Paraesthesia—Carmustine—malignant glioma	0.00115	0.00354	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00113	0.00347	CcSEcCtD
Maraviroc—Insomnia—Temozolomide—malignant glioma	0.00112	0.00344	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.00112	0.00472	CbGpPWpGaD
Maraviroc—Decreased appetite—Carmustine—malignant glioma	0.00111	0.00342	CcSEcCtD
Maraviroc—Paraesthesia—Temozolomide—malignant glioma	0.00111	0.00342	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Carmustine—malignant glioma	0.00111	0.0034	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—AKT1—malignant glioma	0.0011	0.00467	CbGpPWpGaD
Maraviroc—Constipation—Carmustine—malignant glioma	0.0011	0.00337	CcSEcCtD
Maraviroc—Pain—Carmustine—malignant glioma	0.0011	0.00337	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CCR4—malignant glioma	0.00109	0.00461	CbGpPWpGaD
Maraviroc—Decreased appetite—Temozolomide—malignant glioma	0.00108	0.00331	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00107	0.00329	CcSEcCtD
Maraviroc—Fatigue—Temozolomide—malignant glioma	0.00107	0.00328	CcSEcCtD
Maraviroc—Constipation—Temozolomide—malignant glioma	0.00106	0.00325	CcSEcCtD
Maraviroc—Pain—Temozolomide—malignant glioma	0.00106	0.00325	CcSEcCtD
Maraviroc—Gastrointestinal pain—Carmustine—malignant glioma	0.00105	0.00322	CcSEcCtD
Maraviroc—Abdominal pain—Carmustine—malignant glioma	0.00101	0.00311	CcSEcCtD
Maraviroc—Body temperature increased—Carmustine—malignant glioma	0.00101	0.00311	CcSEcCtD
Maraviroc—Gastrointestinal pain—Temozolomide—malignant glioma	0.00101	0.00311	CcSEcCtD
Maraviroc—CCR5—Disease—HEY2—malignant glioma	0.000994	0.0042	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL8—malignant glioma	0.000989	0.00418	CbGpPWpGaD
Maraviroc—Body temperature increased—Temozolomide—malignant glioma	0.000979	0.00301	CcSEcCtD
Maraviroc—Abdominal pain—Temozolomide—malignant glioma	0.000979	0.00301	CcSEcCtD
Maraviroc—CCR5—Disease—IDH1—malignant glioma	0.000971	0.0041	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP2C18—malignant glioma	0.000965	0.00408	CbGpPWpGaD
Maraviroc—CYP3A4—Irinotecan Pathway—APC—malignant glioma	0.000956	0.00404	CbGpPWpGaD
Maraviroc—Hypersensitivity—Carmustine—malignant glioma	0.000944	0.0029	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MDK—malignant glioma	0.00093	0.00393	CbGpPWpGaD
Maraviroc—CCR5—Disease—HEY1—malignant glioma	0.000921	0.00389	CbGpPWpGaD
Maraviroc—Asthenia—Carmustine—malignant glioma	0.000919	0.00283	CcSEcCtD
Maraviroc—Hypersensitivity—Temozolomide—malignant glioma	0.000912	0.0028	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2B6—malignant glioma	0.0009	0.0038	CbGpPWpGaD
Maraviroc—CCR5—Disease—HIST1H3B—malignant glioma	0.000894	0.00378	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCR3—malignant glioma	0.000893	0.00377	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP2B6—malignant glioma	0.000888	0.00375	CbGpPWpGaD
Maraviroc—Asthenia—Temozolomide—malignant glioma	0.000888	0.00273	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—DTX1—malignant glioma	0.000887	0.00375	CbGpPWpGaD
Maraviroc—Diarrhoea—Carmustine—malignant glioma	0.000877	0.00269	CcSEcCtD
Maraviroc—Pruritus—Temozolomide—malignant glioma	0.000876	0.00269	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—F2—malignant glioma	0.00085	0.00359	CbGpPWpGaD
Maraviroc—Dizziness—Carmustine—malignant glioma	0.000847	0.0026	CcSEcCtD
Maraviroc—Diarrhoea—Temozolomide—malignant glioma	0.000847	0.0026	CcSEcCtD
Maraviroc—Dizziness—Temozolomide—malignant glioma	0.000819	0.00252	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—BDKRB2—malignant glioma	0.000817	0.00345	CbGpPWpGaD
Maraviroc—CCR5—Disease—JAG2—malignant glioma	0.000817	0.00345	CbGpPWpGaD
Maraviroc—Vomiting—Carmustine—malignant glioma	0.000815	0.0025	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCR3—malignant glioma	0.000811	0.00343	CbGpPWpGaD
Maraviroc—Rash—Carmustine—malignant glioma	0.000808	0.00248	CcSEcCtD
Maraviroc—Dermatitis—Carmustine—malignant glioma	0.000807	0.00248	CcSEcCtD
Maraviroc—Headache—Carmustine—malignant glioma	0.000803	0.00247	CcSEcCtD
Maraviroc—Vomiting—Temozolomide—malignant glioma	0.000787	0.00242	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.000787	0.00332	CbGpPWpGaD
Maraviroc—Rash—Temozolomide—malignant glioma	0.000781	0.0024	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	0.00078	0.0033	CbGpPWpGaD
Maraviroc—Dermatitis—Temozolomide—malignant glioma	0.00078	0.0024	CcSEcCtD
Maraviroc—Headache—Temozolomide—malignant glioma	0.000776	0.00238	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	0.00077	0.00325	CbGpPWpGaD
Maraviroc—Nausea—Carmustine—malignant glioma	0.000761	0.00234	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—KNG1—malignant glioma	0.000743	0.00314	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—BDKRB2—malignant glioma	0.000742	0.00313	CbGpPWpGaD
Maraviroc—Nausea—Temozolomide—malignant glioma	0.000735	0.00226	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.00073	0.00308	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SUFU—malignant glioma	0.000705	0.00298	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HEY2—malignant glioma	0.000696	0.00294	CbGpPWpGaD
Maraviroc—CCR5—Disease—H3F3A—malignant glioma	0.000691	0.00292	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GFAP—malignant glioma	0.00068	0.00287	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KNG1—malignant glioma	0.000675	0.00285	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SPHK1—malignant glioma	0.000658	0.00278	CbGpPWpGaD
Maraviroc—CCR5—Disease—JAG1—malignant glioma	0.000651	0.00275	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HEY1—malignant glioma	0.000645	0.00272	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCR4—malignant glioma	0.000645	0.00272	CbGpPWpGaD
Maraviroc—CCR5—Disease—FBXW7—malignant glioma	0.000638	0.0027	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000633	0.00267	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HIST1H3B—malignant glioma	0.000626	0.00265	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL8—malignant glioma	0.000599	0.00253	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MMP3—malignant glioma	0.000598	0.00253	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JAG2—malignant glioma	0.000572	0.00242	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CAT—malignant glioma	0.000527	0.00222	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN2B—malignant glioma	0.0005	0.00211	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—H3F3A—malignant glioma	0.000484	0.00204	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—F2—malignant glioma	0.00048	0.00203	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000479	0.00203	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCR3—malignant glioma	0.000479	0.00202	CbGpPWpGaD
Maraviroc—CCR5—Disease—HES1—malignant glioma	0.000477	0.00202	CbGpPWpGaD
Maraviroc—CCR5—Disease—NCOR1—malignant glioma	0.000474	0.002	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—YWHAE—malignant glioma	0.000466	0.00197	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NTRK2—malignant glioma	0.000466	0.00197	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FLT1—malignant glioma	0.000464	0.00196	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—DUSP6—malignant glioma	0.000462	0.00195	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CG—malignant glioma	0.00046	0.00194	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JAG1—malignant glioma	0.000456	0.00193	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH3—malignant glioma	0.000454	0.00192	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFRA—malignant glioma	0.000454	0.00192	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.000454	0.00192	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FBXW7—malignant glioma	0.000447	0.00189	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BDKRB2—malignant glioma	0.000438	0.00185	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—F2—malignant glioma	0.000436	0.00184	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT2—malignant glioma	0.000421	0.00178	CbGpPWpGaD
Maraviroc—CCR5—Disease—TERT—malignant glioma	0.000418	0.00177	CbGpPWpGaD
Maraviroc—CCR5—Disease—HLA-A—malignant glioma	0.000418	0.00177	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CG—malignant glioma	0.000417	0.00176	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PTPN11—malignant glioma	0.00041	0.00173	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFB—malignant glioma	0.000408	0.00172	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH2—malignant glioma	0.000407	0.00172	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGFR1—malignant glioma	0.000406	0.00172	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CD—malignant glioma	0.000404	0.00171	CbGpPWpGaD
Maraviroc—CCR5—Disease—HIF1A—malignant glioma	0.0004	0.00169	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KNG1—malignant glioma	0.000399	0.00168	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2B6—malignant glioma	0.000388	0.00164	CbGpPWpGaD
Maraviroc—CCR5—Disease—CAV1—malignant glioma	0.000387	0.00163	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2B6—malignant glioma	0.000382	0.00162	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT2—malignant glioma	0.000382	0.00161	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NTRK1—malignant glioma	0.00038	0.00161	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—malignant glioma	0.000367	0.00155	CbGpPWpGaD
Maraviroc—CCR5—Disease—BAD—malignant glioma	0.000364	0.00154	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOTCH1—malignant glioma	0.00036	0.00152	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP3—malignant glioma	0.000353	0.00149	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD80—malignant glioma	0.000353	0.00149	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—malignant glioma	0.000352	0.00149	CbGpPWpGaD
Maraviroc—CCR5—Disease—APC—malignant glioma	0.000352	0.00149	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN2B—malignant glioma	0.00035	0.00148	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGF—malignant glioma	0.000348	0.00147	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTPN11—malignant glioma	0.000346	0.00146	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTK2—malignant glioma	0.00034	0.00144	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—malignant glioma	0.000339	0.00143	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2C18—malignant glioma	0.000336	0.00142	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HES1—malignant glioma	0.000334	0.00141	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NCOR1—malignant glioma	0.000332	0.0014	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2C18—malignant glioma	0.000331	0.0014	CbGpPWpGaD
Maraviroc—CCR5—Disease—BRAF—malignant glioma	0.000331	0.0014	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RAF1—malignant glioma	0.000328	0.00138	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—malignant glioma	0.000324	0.00137	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT2—malignant glioma	0.000322	0.00136	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—malignant glioma	0.00032	0.00135	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFRA—malignant glioma	0.000318	0.00134	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CD—malignant glioma	0.00031	0.00131	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SPP1—malignant glioma	0.000309	0.0013	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—malignant glioma	0.000307	0.0013	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGF2—malignant glioma	0.000296	0.00125	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—malignant glioma	0.000294	0.00124	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TERT—malignant glioma	0.000293	0.00124	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—MDM2—malignant glioma	0.000291	0.00123	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFB—malignant glioma	0.000286	0.00121	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGFR1—malignant glioma	0.000284	0.0012	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HIF1A—malignant glioma	0.00028	0.00118	CbGpPWpGaD
Maraviroc—CCR5—Disease—MDM2—malignant glioma	0.000277	0.00117	CbGpPWpGaD
Maraviroc—CCR5—Disease—RAF1—malignant glioma	0.000276	0.00117	CbGpPWpGaD
Maraviroc—CCR5—Disease—ERBB2—malignant glioma	0.000273	0.00116	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—malignant glioma	0.000272	0.00115	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CAV1—malignant glioma	0.000271	0.00114	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CB—malignant glioma	0.00027	0.00114	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KDR—malignant glioma	0.000268	0.00113	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—malignant glioma	0.000267	0.00113	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—F2—malignant glioma	0.000258	0.00109	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FN1—malignant glioma	0.000258	0.00109	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—PTGS1—malignant glioma	0.000255	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BAD—malignant glioma	0.000255	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH1—malignant glioma	0.000252	0.00107	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CD80—malignant glioma	0.000247	0.00104	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APC—malignant glioma	0.000247	0.00104	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—malignant glioma	0.000247	0.00104	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGF—malignant glioma	0.000244	0.00103	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTPN11—malignant glioma	0.000242	0.00102	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—malignant glioma	0.000233	0.000985	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BRAF—malignant glioma	0.000232	0.00098	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT2—malignant glioma	0.000226	0.000953	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—malignant glioma	0.000225	0.000949	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—malignant glioma	0.000217	0.000916	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—malignant glioma	0.000215	0.000907	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KRAS—malignant glioma	0.000212	0.000897	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT3—malignant glioma	0.000209	0.000881	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF2—malignant glioma	0.000208	0.000877	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—malignant glioma	0.000195	0.000824	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MDM2—malignant glioma	0.000194	0.000821	CbGpPWpGaD
Maraviroc—CCR5—Disease—MYC—malignant glioma	0.000194	0.000819	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RAF1—malignant glioma	0.000194	0.000818	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB2—malignant glioma	0.000191	0.000809	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—RTEL1—malignant glioma	0.00019	0.000805	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGFR—malignant glioma	0.00019	0.000801	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—malignant glioma	0.000189	0.000799	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—malignant glioma	0.000188	0.000796	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—malignant glioma	0.000186	0.000785	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL8—malignant glioma	0.000182	0.000767	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—malignant glioma	0.000179	0.000757	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—malignant glioma	0.000175	0.000741	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP3—malignant glioma	0.000174	0.000734	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—malignant glioma	0.000174	0.000733	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CA—malignant glioma	0.000165	0.000695	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—malignant glioma	0.000164	0.000694	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—malignant glioma	0.000163	0.00069	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—malignant glioma	0.000159	0.000673	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—malignant glioma	0.000147	0.000623	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT3—malignant glioma	0.000146	0.000617	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MYC—malignant glioma	0.000136	0.000573	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT1—malignant glioma	0.000134	0.000568	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—malignant glioma	0.000133	0.000561	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KRAS—malignant glioma	0.000125	0.00053	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—malignant glioma	0.000115	0.000487	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—malignant glioma	0.000111	0.000471	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—COX8A—malignant glioma	0.000109	0.000462	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—malignant glioma	9.41e-05	0.000398	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ASMT—malignant glioma	9.3e-05	0.000393	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BCAN—malignant glioma	8.75e-05	0.00037	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—IDH2—malignant glioma	7.05e-05	0.000298	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2B6—malignant glioma	6.63e-05	0.00028	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—IDH1—malignant glioma	6.06e-05	0.000256	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SPHK1—malignant glioma	5.87e-05	0.000248	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2C18—malignant glioma	5.75e-05	0.000243	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—malignant glioma	4.65e-05	0.000196	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS1—malignant glioma	4.36e-05	0.000184	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BCHE—malignant glioma	4.05e-05	0.000171	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A5—malignant glioma	4e-05	0.000169	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—malignant glioma	3.22e-05	0.000136	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CAT—malignant glioma	3.14e-05	0.000132	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOR1—malignant glioma	2.96e-05	0.000125	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CAV1—malignant glioma	2.41e-05	0.000102	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.2e-05	9.29e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—malignant glioma	2.12e-05	8.97e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.93e-05	8.17e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.68e-05	7.12e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—malignant glioma	1.67e-05	7.05e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—malignant glioma	1.46e-05	6.15e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.03e-05	4.34e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—malignant glioma	8.39e-06	3.54e-05	CbGpPWpGaD
